Compare Indonesia Energy Corporation Limited (INDO) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indonesia Energy Corporation Limited vs Neurocrine Biosciences Inc — how do they compare? Indonesia Energy Corporation Limited trades at $3 (market cap $46.01M), while Neurocrine Biosciences Inc trades at $175.74 (market cap $17.40B). The key difference: Neurocrine Biosciences Inc is far larger — about 378.2× Indonesia Energy Corporation Limited's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals.
| INDO | NBIX | |
|---|---|---|
Market Cap | $46.01M | $17.40B |
Sector | Energy | Health |
52-Week High | $6.74 | $180.55 |
52-Week Low | $2.49 | $123.10 |
Enterprise Value | $41.38M | $16.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDO trades at $2.99, down 1.32% today, with a bullish technical signal from moving averages and oscillators. The company shows negative profitability metrics including -253.4% net income margin but maintains 100% analyst buy ratings. Recent operational milestones include commencement of drilling at the Kruh Block, providing potential catalysts for future revenue growth.
While current financials show significant losses, analyst optimism and recent operational progress suggest turnaround potential. Key risks include execution challenges in oil exploration and sustained negative cash flow. The stock presents speculative opportunity for investors betting on successful well development and future profitability improvement.
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% with strong bullish momentum. Recent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, underscore robust growth. The stock shows bullish technical signals with support at $170 and resistance at $173. Revenue growth accelerated to $2.86 billion in 2025, with net income margin improving to 21.55% in 2026 projections. Positive news highlights pipeline advancements and the Soleno acquisition.
Outlook remains positive with a consensus price target of $196.08, implying 13% upside. Key opportunities include sustained earnings growth and pipeline expansion, while risks involve clinical trial outcomes and competitive pressures. Institutional sentiment is strongly bullish with 86% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
